Relay Therapeutics (RLAY) EBIT (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of EBIT data on file, last reported at -$78.6 million in Q1 2026.

• EBIT for Q1 2026 came in at -$78.6 million, up 7.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$296.5 million (up 19.22% YoY), and the FY2025 annual result was -$302.7 million, up 18.72% from the prior year.
• EBIT eased to -$78.6 million in Q1 2026 per RLAY's latest filing, from -$60.6 million in the prior quarter.
• Over five years, EBIT peaked at -$60.6 million in Q4 2025 and troughed at -$106.0 million in Q2 2023.
• A 5-year average of -$83.9 million and a median of -$84.9 million in 2025 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2023: EBIT jumped 59.8% in 2022, then plunged 61.31% in 2023.
• A 5-year view of EBIT shows it stood at -$72.9 million in 2022, then slipped by 26.55% to -$92.2 million in 2023, then climbed by 7.83% to -$85.0 million in 2024, then climbed by 28.65% to -$60.6 million in 2025, then dropped by 29.62% to -$78.6 million in 2026.
• Business Quant data shows RLAY's EBIT at -$78.6 million in Q1 2026, -$60.6 million in Q4 2025, and -$80.4 million in Q3 2025.